SG 299
Alternative Names: CD8 targeted CD19 fusogen; SG-295; SG-299Latest Information Update: 14 Jul 2025
At a glance
- Originator Sana Biotechnology
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Autoimmune disorders; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 14 Jul 2025 Preclinical development for Chronic lymphocytic leukaemia, Non-Hodgkin's lymphoma and Precursor B-cell lymphoblastic leukaemia-lymphoma is underway in USA
- 28 May 2025 No recent reports of development identified for preclinical development in Chronic-lymphocytic-leukaemia in USA (IV)
- 28 May 2025 No recent reports of development identified for preclinical development in Non-Hodgkin's-lymphoma in USA (IV)